Richard E. Baltz
		Richard.Baltz@aporter.com
		+1 202.942.5124 +1 202.942.5999 Fax
		555 Twelfth Street, NW Washington, DC 20004-1206

September 25, 2013

FOIA CONFIDENTIAL TREATMENT REQUEST

Under 17 CFR §200.83

The entity requesting confidential treatment is:

MacroGenics, Inc.

9640 Medical Center Drive

Rockville, MD 20850

Attn: Scott Koenig, M.D., Ph.D.

President and Chief Executive Officer

301-251-5172

VIA EDGAR SUBMISSION

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Jeffrey P. Riedler

 

Re:

MacroGenics, Inc.

Registration Statement on Form S-1

File No. 333-190994

Ladies and Gentlemen:

On behalf of MacroGenics, Inc. (the “Company”), in order to facilitate your review, we supplementally advise the Staff that the Pricing Committee of the Company’s board of directors has approved a price range of $[**] to $[**] per share of common stock, based on an approved reverse split of 1-for-[**] shares. Disclosure of the price range and the reverse split will be included in the prospectus contained in the next amendment to the Company’s registration statement on Form S-1. The price range, prior to the reverse split, in correlation to the share numbers in the currently filed Form S-1, would be $[**] to $[**] per share of common stock.

 

[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

---

Rule 83 Confidential Treatment Requested by MacroGenics, Inc.

 

 

September 25, 2013

Page 2

If you have any further questions or comments, or if you require any additional information, please contact the undersigned by telephone at (202) 942-5124 or by email at richard.baltz@aporter.com. Thank you for your assistance.

 

 

cc:	Office of Freedom of Information and Privacy Act Operations

Securities and Exchange Commission

100 F Street N.E., Mail Stop 2736

Washington, D.C. 20549